Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 20/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1473832 | 1.00 | IMPDH2 (0.73) | IMPDH2 | |
| SCHEMBL1473475 | 0.85 | IMPDH2 (1.00) | IMPDH2 | |
| SCHEMBL1473618 | 0.83 | IMPDH2 (0.83) | IMPDH2 | |
| SCHEMBL1472656 | 0.82 | IMPDH2 (0.71) | IMPDH2 | |
| SCHEMBL1475417 | 0.81 | IMPDH2 (1.00) | IMPDH2 | |
| SCHEMBL1475860 | 0.81 | IMPDH2 (0.71) | IMPDH2 | |
| SCHEMBL6172206 | 0.80 | IMPDH2 (0.72) | IMPDH2 | |
| SCHEMBL5011161 | 0.80 | IMPDH2 (0.65) | IMPDH2 | |
| SCHEMBL1473187 | 0.80 | IMPDH2 (1.00) | IMPDH2 | |
| SCHEMBL1473135 | 0.79 | IMPDH2 (1.00) | IMPDH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1126843-A4 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL MYERS SQUIBB CO (US) | 2005-06-15 | — | — | EP | claimed |
| US-6399773-B1 | AUTOIMMUNE DISEASE; TRANSPLANTING ORGANS | BRISTOL-MYERS SQUIBB CO. | 2002-06-04 | — | — | US | claimed |
| EP-1126843-A1 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-29 | — | — | EP | claimed |
| WO-2000025780-A1 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS THAT ARE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2000-05-11 | — | — | WO | claimed |
| EP-2803357-B1 | Angiogenesis inhibitors | UNIV JOHNS HOPKINS (US) | 2020-11-18 | — | — | EP | disclosed |
| US-9642865-B2 | Angiogenesis inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-05-09 | — | — | US | disclosed |
| US-8980930-B2 | Angiogenesis inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20150056267-A1 | ANGIOGENESIS INHIBITORS | UNIV JOHNS HOPKINS (US) | 2015-02-26 | — | — | US | disclosed |
| EP-2803357-A2 | Angiogenesis inhibitors | THE JOHNS-HOPKINS UNIVERSITY (US) | 2014-11-19 | — | — | EP | disclosed |
| US-20130101657-A1 | ANGIOGENESIS INHIBITORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2013-04-25 | — | — | US | disclosed |
| US-7915255-B2 | Metabolism-modulating agents and uses therefor | VERVA PHARMACEUTICALS PTY LTD (AU) | 2011-03-29 | — | — | US | disclosed |
| US-20080193499-A1 | Angiogenesis Inhibitors | THE JOHNS HOPKINS UNIVERSITY (US) | 2008-08-14 | — | — | US | disclosed |
| EP-1786415-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2007-05-23 | — | — | EP | disclosed |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | UNIVERSITY OF QUEENSLAND (AU) | 2006-05-18 | — | — | US | disclosed |
| WO-2006017896-A1 | METABOLISM-MODULATING AGENTS AND USES THEREFOR | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-02-23 | — | — | WO | disclosed |
| US-6399773-B1 | AUTOIMMUNE DISEASE; TRANSPLANTING ORGANS | BRISTOL-MYERS SQUIBB CO. | 2002-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150056267-A1 | ANGIOGENESIS INHIBITORS | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885 |
| US-20080193499-A1 | Angiogenesis Inhibitors | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885 |
| US-20130101657-A1 | ANGIOGENESIS INHIBITORS | FLT1, VEGFA, FLT4 | IMPDH2 2862/4885 |
| US-20060106097-A1 | Metabolism-modulating agents and uses therefor | IMPDH1, IMPDH2, HADHB | IMPDH2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.